C. Gardner

发表

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

P. Beale, N. Bleehen, P. Vasey, 1999, British Journal of Cancer.

A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule

J. Carmichael, J. Houghton, P. Woll, 2001, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours

M. Ranson, L. Gumbrell, P. Khan, 2000, British Journal of Cancer.